CompanyGraph
Jacobio Pharmaceuticals Group Co., Ltd.
1167 · HKEX · China
Price data from its 77V listing on XSTU, quoted in EUR
jacobiopharma.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $73.01M, above the global median of $18.69M
- PositionOperating margin is 85%, higher than 95% of its Biotechnology peers (median -45.9%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.27BHKD799.68M · vs all stocks (USD)
Trailing P/E
6.97xvs Biotechnology peers
Revenue (TTM)
866.66MHKD110.47M · vs all stocks (USD)
Profit Margin
69.53%vs Biotechnology peers
Beta
0.3460xvs all stocks
52-Week Change
-36.64%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
6.27BHKD799.68M · vs all stocks (USD)
Enterprise Value
3.02BHKD384.53M · vs all stocks (USD)
Trailing P/E
6.97xvs Biotechnology peers
Forward P/E
-178.21xvs Biotechnology peers
Price to Sales (TTM)
5.53xvs Biotechnology peers
Price to Book (MRQ)
2.58xvs Biotechnology peers
Enterprise to Revenue
3.48xvs Biotechnology peers
Enterprise to EBITDA
4.83xvs Biotechnology peers
Profit Margin
69.53%vs Biotechnology peers
Operating Margin
84.98%vs Biotechnology peers
Return on Assets (TTM)
20.59%vs Biotechnology peers
Return on Equity (TTM)
46.30%vs Biotechnology peers
Revenue (TTM)
866.66MHKD110.47M · vs all stocks (USD)
Revenue per Share (TTM)
0.9540HKDUpdated Oct 20, 2026Quarterly Revenue Growth
1500.50%vs Biotechnology peers
Gross Profit (TTM)
844.66MHKD107.67M · vs all stocks (USD)
EBITDA (TTM)
624.09MHKD79.55M · vs all stocks (USD)
Net Income (TTM)
602.58MHKD76.81M · vs all stocks (USD)
Operating Cash Flow (TTM)
615.99MHKD78.52M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
572.73MHKD73.01M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00HKDUpdated Oct 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
53.52MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
593.00KCNYFY2025 · Dec 31, 2025Gross Profit
52.93MCNYFY2025 · Dec 31, 2025Operating Income
-166.24MCNY-24.99M · vs all stocks (USD)
Pre-tax Income
-145.98MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-145.98MCNYFY2025 · Dec 31, 2025EBIT
-133.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-128.51MCNYFY2025 · Dec 31, 2025Research & Development
188.59MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
8.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
31.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.94MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1900CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
774.51MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
774.51MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-145.98MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-167.38MCNYFY2025 · Dec 31, 2025Free Cash Flow
-168.48MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
373.78MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-145.98MCNYFY2025 · Dec 31, 2025Stock-based Compensation
4.48MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-18.76MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.70MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-414.00KCNYFY2025 · Dec 31, 2025Capital Expenditures
-1.10MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-567.00KCNYFY2025 · Dec 31, 2025Net Acquisitions
114.54MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.62BCNYFY2025 · Dec 31, 2025Sale of Investments
2.37BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-141.75MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
114.87MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-92.17MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-11.28MCNYFY2025 · Dec 31, 2025Other Financing Charges
45.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
56.43MCNYFY2025 · Dec 31, 2025Shares Outstanding
787.06MSharesUpdated Oct 20, 2026Float Shares
408.98MSharesUpdated Oct 20, 2026% Held by Insiders
35.75%vs all stocks
% Held by Institutions
8.96%vs all stocks
Total Cash (MRQ)
1.97BHKD251.25M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.15HKDUpdated Oct 20, 2026Total Debt (MRQ)
187.48MHKD23.90M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1182xvs Biotechnology peers
Current Ratio (MRQ)
8.28xvs Biotechnology peers
Book Value per Share (MRQ)
2.02HKDUpdated Oct 20, 2026Total Assets
1.30BCNY196.04M · vs all stocks (USD)
Total Current Assets
1.15BCNYFY2025 · Dec 31, 2025Total Liabilities
533.70MCNYFY2025 · Dec 31, 2025Total Non-current Assets
150.54MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
307.40MCNYFY2025 · Dec 31, 2025Total Current Liabilities
226.29MCNYFY2025 · Dec 31, 2025Cash
373.78MCNYFY2025 · Dec 31, 2025Cash Equivalents
569.88MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
943.65MCNYFY2025 · Dec 31, 2025Other Short-term Investments
160.03MCNYFY2025 · Dec 31, 2025Accounts Receivable
8.89MCNYFY2025 · Dec 31, 2025Accounts Payable
43.52MCNYFY2025 · Dec 31, 2025Short-term Debt
15.43MCNYFY2025 · Dec 31, 2025Long-term Debt
149.74MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
157.30MCNYFY2025 · Dec 31, 2025Common Stock (Book)
523.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-3.50BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
770.63MCNY115.83M · vs all stocks (USD)
Treasury Stock
15.84MCNYFY2025 · Dec 31, 202552-Week Low
3.98HKDUpdated Oct 20, 202652-Week High
9.29HKDUpdated Oct 20, 202652-Week Change
-36.64%vs all stocks
Beta
0.3460xvs all stocks
50-Day MA
5.75HKDUpdated Oct 20, 2026200-Day MA
5.92HKDUpdated Oct 20, 2026Avg 10-Day Volume
1.37MSharesUpdated Oct 20, 2026Avg 30-Day Volume
1.40MSharesUpdated Oct 20, 2026Diluted EPS (TTM)
0.7500HKDUpdated Oct 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 85%, higher than 95% of its Biotechnology peers (median -45.9%)Significant
Operating margin: 0.85Industry median: -0.46Industry P95: 0.29Peers compared: 255
Profit margin is 69.5%, higher than 95% of its Biotechnology peers (median -63.8%)Significant
Profit margin: 0.70Industry median: -0.64Industry P95: 0.36Peers compared: 255
Return on equity is 46.3%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Return on equity: 0.46Industry median: -0.24Industry P95: 0.18Peers compared: 255
Return on assets is 20.6%, higher than 95% of its Biotechnology peers (median -20.5%)Significant
Return on assets: 0.21Industry median: -0.21Industry P95: 0.14Peers compared: 255
Financial Health
Altman Z-Score 2.8: safe zoneNotable
Altman Z-Score: 2.80
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $73.01M, above the global median of $18.69MNotable
Levered free cash flow (USD): 73,005,652.947Global Median: 18,689,872.41
Companies that share the same coordination system — how they create, deliver, or capture value.
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
LivsMed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
TORM PLC
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Trane Technologies plc
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Hubei Feilihua Quartz Glass Co. Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated